Venetoclax to Augment Epigenetic Modification and Chemotherapy

NCT05317403 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory

Interventions

DRUG: Venetoclax
DRUG: Azacitadine
DRUG: Vorinostat
DRUG: Cytarabine
DRUG: Fludarabine
DRUG: Filgrastim

Sponsor

Medical College of Wisconsin